Form 4: Applied Therapeutics CMO Granted 300,000 Restricted Stock Units

Applied Therapeutics, Inc.'s Chief Medical Officer, Evan Prescott Bailey, was granted 300,000 compensatory Restricted Stock Units, vesting over time, as disclosed in a recent SEC Form 4 filing.

Summary

• Evan Prescott Bailey, Chief Medical Officer of Applied Therapeutics, Inc. (APLT), was granted 300,000 shares in the form of compensatory Restricted Stock Units (RSUs).
• The transaction date for this grant was June 15, 2025.
• These RSUs were granted under the company's 2019 Equity Incentive Plan, with each RSU representing a contingent right to receive one share of common stock.
• Following this transaction, Mr. Bailey beneficially owns 841,669 shares of common stock.
• The vesting schedule for the RSUs is as follows: one-fourth (1/4th) will vest on June 15, 2026, with the remaining shares vesting in equal quarterly installments thereafter, contingent upon Mr. Bailey's continued service to the company.

Sentiment

Score: 7

Explanation: The grant of a significant number of Restricted Stock Units to a key executive like the Chief Medical Officer is generally a positive signal, indicating management retention and alignment with long-term company performance, although it does imply future dilution.

Positives

• The grant of 300,000 Restricted Stock Units to the Chief Medical Officer aligns his long-term interests with those of shareholders, promoting retention and performance.
• The vesting schedule, tied to continued service, incentivizes the CMO to remain with the company and contribute to its long-term success.

Negatives

• The RSU grant, upon vesting and conversion to common stock, will result in a degree of share dilution for existing shareholders.

Risks

• The vesting of RSUs is contingent on the Reporting Person continuing to provide services; a departure before full vesting would result in forfeiture of unvested units.
• Future stock price fluctuations could impact the ultimate value of the RSU grant to the Chief Medical Officer.

Future Outlook

The document outlines a future vesting schedule for the granted Restricted Stock Units, with the first tranche vesting on June 15, 2026, and subsequent tranches vesting quarterly thereafter, contingent on the Chief Medical Officer's continued service.

Industry Context

This RSU grant is a standard form of executive compensation in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize key talent by aligning their long-term interests with company performance and shareholder value.

Stakeholder Impact

• Shareholders: Potential future dilution upon RSU vesting, but also benefit from incentivized executive performance and retention.
• Employees (specifically the CMO): Direct financial benefit tied to company performance and continued employment.

Next Steps

• Vesting of 1/4th of the compensatory RSUs on June 15, 2026.
• Subsequent vesting of remaining RSUs in equal quarterly installments after June 15, 2026, subject to continued service.

Key Dates

Keywords

Applied Therapeutics, APLT, Restricted Stock Units, RSU, Insider Transaction, SEC Form 4, Executive Compensation, Chief Medical Officer, Equity Incentive Plan, Vesting